Safety, efficacy and immunogenicity of autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma.

Trial Profile

Safety, efficacy and immunogenicity of autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs HSP105 peptide-loaded dendritic cell vaccine (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2011 Planned end date (Mar 2012) added as reported by University Hospital Medical Information Network - Japan record.
    • 13 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top